Scientists identify DNA signature linked to prostate cancer severity
January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.
BRCA2 gene implicated in rare but lethal prostate cancer
January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer. Funded by Prostate Cancer Canada and led by Dr. Robert Bristow of the Princess Margaret Cancer Centre in Toronto, the findings were published today in Nature Communications:
Thank You to our Canadian Mo Bros and Sistas!
TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign. Here in Canada, enthusiasm was on display in many forms, from spirited move challenges like 24-hour runs and epic host events like Suits & Staches in Toronto, to the first ever online host event of 24-hour gaming streams with EA Sports and over 60,000 official moustaches.
The Parking Lot Prostate Exam Project #TalkProstate
To stimulate public discussion about prostate cancer and the importance of early detection, Prostate Cancer Canada teamed up with FCB Canada and CFL legend Damon Allen during Prostate Cancer Awareness Month to help get a serious message across through a fun campaign.
Interpreting the study on early prostate cancer survival with Urologist and prostate cancer expert, Dr. Fred Saad
Toronto, ON – September 19, 2016: A study published last week in the New England Journal of Medicine followed men with localized (contained to the prostate) prostate cancer for 10 years as they underwent one of three randomized treatment streams has since been widely reported on. Notably, many of the headlines touched upon the same reassuring conclusion: whether participants were treated with radiation therapy, had their prostates removed altogether, or were simply monitored using Prostate-Specific Antigen (PSA) tests, survival after ten years was the same at 99 per cent.
The future of prostate cancer research looks bright
Toronto, ON – September 19, 2016: Continuing with its ongoing commitment to ensure the future of prostate cancer research in Canada is left in the best possible hands, Prostate Cancer Canada (PCC) has chosen four postdoctoral fellows and one PhD candidate as the recipients for this year’s prestigious personnel awards.
Plaid for Dad becoming a Canadian Father's Day tradition
July 8, 2016 – TORONTO, ON – In only its second year, Prostate Cancer Canada’s (PCC) Plaid For Dad campaign further solidified itself as the way Canadians are choosing to give back each Father’s Day weekend. Growing from 200 to over 600 participating workplaces across the country, the number of Canadians who wore plaid to raise awareness and research funds for prostate cancer rose significantly in just a year’s time.
A Walk to Remember
CALGARY, ALBERTA – June 20th, 2016 – Friends, families and survivors from across the country joined Prostate Cancer Canada this Father’s Day, unified by one goal – to raise funds and awareness for prostate cancer.
Team Eberle, led by Jordan Eberle of the Edmonton Oilers, show their enthusiasm at the Calgary Walk Run.
#PlaidForDad Sweeps the Nation
JUNE 17TH, 2016 – TORONTO, ON – After a successful inaugural year that yielded over 200 Canadian workplaces and evolved into a wide scale social media movement, #PlaidforDad has returned in a big way to raise research funds and awareness for the most common cancer in men. Over 600 workplaces across all sectors representing hundreds of thousands of individuals across Canada are wearing Plaid for Dad today to do their part in raising vital research funds to improve the way we detect, treat and support Canadian men and their families faced with the disease.
Active surveillance pioneer seeks to improve prostate cancer biopsies
The man who is credited with coining the term active surveillance, Dr. Laurence Klotz of the Sunnybrook Research Institute, is leading a team focused on improving the way we biopsy for prostate cancer. The Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada today announced, in partnership, $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects.